Asmis Lars M, Asmis Reto, Sulzer Irmela, Furlan Miha, Lämmle Bernhard
Division of Haematology and Central Haematology Laboratory, Inselspital, Berne, Switzerland.
Swiss Med Wkly. 2008 Mar 8;138(9-10):142-9. doi: 10.4414/smw.2008.11788.
This pilot study seeks to determine whether contact system activation (CSA) occurs in human sepsis patients and to characterise blood levels of the 47kD light chain of high-molecular weight kininogen (47kD HK).
Six consecutive patients with clinical suspicion of sepsis were evaluated on days 1, 2, 3 and 6-8 for 47kD HK blood levels expressed in U/ml of whole blood and as percent of total HK. 47kD HK was measured in whole blood by quantitative immunoblot analysis.
On study day 1 or 2, analysis of 47kD HK in U/ml of whole blood identified CSA in 3/6 patients. When 47kD HK levels were expressed as percent of total HK, 4/6 patients were identified with CSA before day 3. The degree of CSA as assayed by the presence of 47kD HK correlated with the severity of the systemic inflammatory syndrome (SIRS), i.e. mean CSA increased progressively from basal levels in healthy controls (0.08 U/ml or 10.4%) to patients without SIRS (0.10 U/ml or 15.1%), to patients with sepsis (0.12 U/ml or 15.0%), and finally to patients in a combined category of severe sepsis and septic shock (0.13 U/ml or 17.4%).
CSA, defined by increased 47kD HK, occurred early on in the course of sepsis in a subset of sepsis patients. 47kD HK levels, an indicator of bradykinin release, correlated with sepsis severity. Future larger studies will need to evaluate the role of 47kD HK as a biomarker for both prognosis and treatment response in human sepsis..
本初步研究旨在确定人类脓毒症患者是否发生接触系统激活(CSA),并对高分子量激肽原47kD轻链(47kD HK)的血液水平进行特征描述。
对6例临床怀疑为脓毒症的连续患者在第1、2、3及6 - 8天进行评估,检测以全血U/ml表示的47kD HK血液水平以及其占总HK的百分比。通过定量免疫印迹分析测定全血中的47kD HK。
在研究第1天或第2天,以全血U/ml分析47kD HK时,6例患者中有3例被确定发生CSA。当47kD HK水平以占总HK的百分比表示时,在第3天之前6例患者中有4例被确定发生CSA。通过47kD HK的存在检测到的CSA程度与全身炎症综合征(SIRS)的严重程度相关,即平均CSA从健康对照的基础水平(0.08 U/ml或10.4%)逐渐升高至无SIRS的患者(0.10 U/ml或15.1%)、脓毒症患者(0.12 U/ml或15.0%),最终升至严重脓毒症和脓毒性休克合并组的患者(0.13 U/ml或17.4%)。
由47kD HK增加所定义的CSA在一部分脓毒症患者病程早期就已发生。47kD HK水平作为缓激肽释放的指标,与脓毒症严重程度相关。未来更大规模的研究需要评估47kD HK作为人类脓毒症预后和治疗反应生物标志物的作用。